[go: up one dir, main page]

EE200200401A - Drospirenoon hormoonasendusraviks - Google Patents

Drospirenoon hormoonasendusraviks

Info

Publication number
EE200200401A
EE200200401A EEP200200401A EEP200200401A EE200200401A EE 200200401 A EE200200401 A EE 200200401A EE P200200401 A EEP200200401 A EE P200200401A EE P200200401 A EEP200200401 A EE P200200401A EE 200200401 A EE200200401 A EE 200200401A
Authority
EE
Estonia
Prior art keywords
drospirenone
composition
replacement therapy
hormone replacement
further embodiment
Prior art date
Application number
EEP200200401A
Other languages
English (en)
Inventor
Heil Wolfgang
Hilmann J�rgen
Lipp Ralph
Sch�rmann Rolf
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26071749&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE200200401(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of EE200200401A publication Critical patent/EE200200401A/et
Publication of EE05533B1 publication Critical patent/EE05533B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
EEP200200401A 2000-01-18 2001-01-18 Farmatseutiline kompositsioon ja preparaat, mis sisaldab mikroniseeritud drospirenooni ja ”strogeeni ning nende kasutamine EE05533B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48402600A 2000-01-18 2000-01-18
EP00200183 2000-01-18
PCT/IB2001/000041 WO2001052857A1 (en) 2000-01-18 2001-01-18 Drospirenone for hormone replacement therapy

Publications (2)

Publication Number Publication Date
EE200200401A true EE200200401A (et) 2003-10-15
EE05533B1 EE05533B1 (et) 2012-04-16

Family

ID=26071749

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200401A EE05533B1 (et) 2000-01-18 2001-01-18 Farmatseutiline kompositsioon ja preparaat, mis sisaldab mikroniseeritud drospirenooni ja ”strogeeni ning nende kasutamine

Country Status (30)

Country Link
EP (2) EP1257280B1 (et)
JP (2) JP5128743B2 (et)
KR (2) KR100913910B1 (et)
CN (2) CN101934078A (et)
AT (2) ATE442147T1 (et)
AU (3) AU2001225413B2 (et)
BG (1) BG65849B1 (et)
BR (1) BR0107683A (et)
CA (1) CA2394165C (et)
CY (1) CY1109567T1 (et)
CZ (1) CZ20022411A3 (et)
DE (2) DE60139907D1 (et)
DK (2) DK1257280T3 (et)
EE (1) EE05533B1 (et)
ES (2) ES2332226T3 (et)
HK (1) HK1047248B (et)
HU (1) HUP0204291A3 (et)
IL (3) IL150775A0 (et)
ME (1) ME00292B (et)
MX (1) MXPA02006613A (et)
NO (1) NO335570B1 (et)
NZ (1) NZ520630A (et)
PL (1) PL201878B1 (et)
PT (1) PT1611892E (et)
RS (1) RS52149B (et)
RU (2) RU2275198C2 (et)
SI (2) SI1611892T1 (et)
SK (2) SK288129B6 (et)
WO (1) WO2001052857A1 (et)
ZA (2) ZA200206551B (et)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50262B2 (sr) * 1999-08-31 2018-10-31 Bayer Pharma AG Farmaceutska kombinacija etinilestradiola i drospirenona za primenu kao kontraceptivnog sredstva
EP1216713A1 (en) * 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
WO2003006027A1 (en) 2001-07-13 2003-01-23 Schering Aktiengesellschaft Combination of drospirenone and an estrogen sulphamate for hrt
US20030229057A1 (en) * 2002-03-11 2003-12-11 Caubel Patrick Michel Continuous sulfatase inhibiting progestogen hormone replacement therapy
HRP20041121A2 (en) * 2002-04-26 2005-02-28 Schering Aktiengesellschaft Treatment of hypertension in women receiving hormone replacement therapy
US7786101B2 (en) 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
AU2002368326A1 (en) * 2002-11-05 2004-06-07 Schering Aktiengesellschaft Hormone replacement therapy with drospirenone
DE60330888D1 (de) * 2002-11-05 2010-02-25 Bayer Schering Pharma Ag Verwendung von drospirenon zur behandlung von hypertension
MY142989A (en) 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
ES2325591T3 (es) 2004-03-10 2009-09-09 Bayer Schering Pharma Aktiengesellschaft Composiciones que comprenden drospirenona dispersada molecularmente.
DE102004023984A1 (de) * 2004-05-14 2005-12-08 Hf Arzneimittelforschung Gmbh Filmförmiges, oral zu verabreichendes Arzneimittel, enthaltend Estriol
US8022053B2 (en) 2004-11-02 2011-09-20 Bayer Schering Pharma Aktiengesellschaft Oral solid dosage forms containing a low dose of estradiol
EP1954240A2 (en) * 2005-07-15 2008-08-13 Bayer Schering Pharma Aktiengesellschaft Drospirenone containing transdermal drug delivery devices and methods of delivery thereof
DE102005056527A1 (de) * 2005-11-25 2007-07-12 Grünenthal GmbH Verwendung einer Kombination aus Ethinylestradiol und Chlormadinonacetat zur Herstellung eines Arzneimittels
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
CN101489563A (zh) * 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
DE102007011105A1 (de) 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
CN101623287B (zh) * 2008-07-07 2012-02-08 天津金耀集团有限公司 一种屈螺酮类似物的治疗更年期综合症的药物组合物
ES2344675B1 (es) * 2008-12-19 2011-04-28 Italfarmaco, S.A. Uso de estriol en la preparacion de una formulacion farrmaceutica para el tratamiento de atrofia vaginal en mujeres con riesgo de patologiacardiovascular.
UY32836A (es) 2009-08-12 2011-03-31 Bayer Schering Pharma Ag Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato
BR112012026115B1 (pt) * 2010-04-15 2019-12-24 Bayer Ip Gmbh forma de dosagem oral sólida, seu uso, e unidade de acondicionamento
ES2533584T3 (es) * 2010-04-15 2015-04-13 Bayer Intellectual Property Gmbh Formas de dosificación oral sólidas de dosis baja para TSH
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
KR20140088197A (ko) 2011-11-04 2014-07-09 바이엘 파마 악티엔게젤샤프트 18-메틸-6,7-메틸렌-3-옥소-17-프레그느-4-엔-21,17β-카르보락톤, 상기 화합물을 함유하는 약제학적 제제 및 자궁내막증 치료에 있어서 이들의 용도
TW201350122A (zh) * 2012-04-23 2013-12-16 Bayer Pharma AG １８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內用途，包含１８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內系統，及其於避孕及婦科治療之用途
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
TW201607943A (zh) 2013-12-19 2016-03-01 拜耳製藥公司 作為ｅｐ４配體之新穎苯并咪唑衍生物
JP6866560B2 (ja) 2015-06-18 2021-04-28 エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ エステトロール成分を含有する口腔内崩壊性投与単位
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
CN110809473A (zh) 2017-06-01 2020-02-18 延世大学校产学协力团 用于预防或治疗骨相关疾病的药物组合物
JOP20200260A1 (ar) * 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
CN115813937B (zh) * 2022-12-01 2025-04-11 南通联亚药业股份有限公司 一种稳定的包含屈螺酮和雌二醇的药物组合物及其制备方法
CN118356456A (zh) * 2024-04-17 2024-07-19 且安生物科技有限责任公司 一种抗炎护巢草本提取制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652761C2 (de) * 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE3022337A1 (de) * 1980-06-11 1982-01-07 Schering Ag Berlin Und Bergkamen, 1000 Berlin Praeparate zur kontrazeption und zur behandlung gynaekologischer stoerungen
JPH07114946B2 (ja) * 1988-10-24 1995-12-13 株式会社奈良機械製作所 難溶性物質の処理方法
JP2859919B2 (ja) * 1990-03-15 1999-02-24 旭化成工業株式会社 難溶性薬物の溶出性改善方法
NL9301562A (nl) * 1993-09-09 1995-04-03 Saturnus Ag Preparaat voor substitutietherapie.
JPH07112928A (ja) * 1993-10-15 1995-05-02 Freunt Ind Co Ltd 難溶性薬物の溶解性改善方法およびそれにより得られた粒状薬剤
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
JP4022269B2 (ja) * 1995-05-26 2007-12-12 協和醗酵工業株式会社 医薬組成物
US5922349A (en) * 1995-09-28 1999-07-13 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
EP0956024B1 (en) * 1996-07-26 2004-07-21 Wyeth Monophasic oral contraceptive method and kit comprising a combination of progestin and estrogen
WO1998004266A1 (en) * 1996-07-26 1998-02-05 American Home Products Corporation Oral contraceptive
DE19633685C1 (de) * 1996-08-12 1997-10-09 Schering Ag Verfahren zur Herstellung von Drospirenon (6beta,7beta;15 beta,16beta-Dimethyl-en-3-oxo-17alpha-pregn-4-en-21,17-carbolacton, DRSP) sowie 7alpha-(3-Hydroxy-1-propyl)-6beta,7beta;15beta, 16beta-dimethylen-5beta-androstan-3beta,5,17beta-triol (ZK 92836) und 6beta,7beta;15beta,16beta-dimethylen-5beta-hydroxy-3-oxo-17alpha-androstan-21,17-carbolacton (90965) als Zwischenprodukte des Verfahrens
DE19654609A1 (de) * 1996-12-20 1998-06-25 Schering Ag Therapeutische Gestagene zur Behandlung von Premenstrual Dysphoric Disorder
JPH10182701A (ja) * 1996-12-26 1998-07-07 Sanei Toka Kk 溶出性向上粉末及びその製造方法
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
RS50262B2 (sr) * 1999-08-31 2018-10-31 Bayer Pharma AG Farmaceutska kombinacija etinilestradiola i drospirenona za primenu kao kontraceptivnog sredstva

Also Published As

Publication number Publication date
JP5128743B2 (ja) 2013-01-23
ATE442147T1 (de) 2009-09-15
HUP0204291A3 (en) 2003-05-28
RU2002122113A (ru) 2004-03-10
MXPA02006613A (es) 2003-10-15
NZ520630A (en) 2004-09-24
BG106915A (bg) 2003-04-30
AU2001225413B2 (en) 2005-06-23
EP1611892B1 (en) 2009-09-09
RU2275198C2 (ru) 2006-04-27
EP1257280A1 (en) 2002-11-20
KR100747965B1 (ko) 2007-08-08
ZA200206551B (en) 2006-04-29
BR0107683A (pt) 2002-11-12
DK1257280T3 (da) 2005-12-12
SK288129B6 (sk) 2013-10-02
MEP38008A (en) 2011-02-10
RS52149B (sr) 2012-08-31
SK287719B6 (en) 2011-07-06
ATE305789T1 (de) 2005-10-15
SI1611892T1 (sl) 2010-01-29
AU2541301A (en) 2001-07-31
DK1611892T3 (da) 2009-11-02
YU54602A (sh) 2006-01-16
HK1047248A1 (en) 2003-02-14
HK1047248B (en) 2005-12-30
JP5563227B2 (ja) 2014-07-30
RU2402331C2 (ru) 2010-10-27
DE60113809T2 (de) 2006-06-22
IL150775A (en) 2008-08-07
JP2003520239A (ja) 2003-07-02
EE05533B1 (et) 2012-04-16
EP1611892A2 (en) 2006-01-04
IL150775A0 (en) 2003-02-12
CN101934078A (zh) 2011-01-05
PL201878B1 (pl) 2009-05-29
ME00292B (me) 2011-05-10
PL356987A1 (en) 2004-07-12
IL191131A0 (en) 2008-11-03
NO20022966L (no) 2002-09-18
ZA200601285B (en) 2008-01-08
PT1611892E (pt) 2009-11-20
DE60139907D1 (de) 2009-10-22
BG65849B1 (bg) 2010-03-31
WO2001052857A1 (en) 2001-07-26
SI1257280T1 (sl) 2006-02-28
JP2009120615A (ja) 2009-06-04
NO20022966D0 (no) 2002-06-20
CY1109567T1 (el) 2014-08-13
HK1082433A1 (en) 2006-06-09
HUP0204291A2 (hu) 2003-04-28
KR100913910B1 (ko) 2009-08-26
EP1257280B1 (en) 2005-10-05
DE60113809D1 (de) 2006-02-16
CA2394165C (en) 2010-04-13
ES2247054T3 (es) 2006-03-01
CN1395488A (zh) 2003-02-05
RU2005140938A (ru) 2007-07-10
SK10322002A3 (sk) 2003-03-04
ES2332226T3 (es) 2010-01-29
AU2005209600B2 (en) 2008-08-07
KR20070051956A (ko) 2007-05-18
NO335570B1 (no) 2014-12-29
CA2394165A1 (en) 2001-07-26
IL191131A (en) 2010-12-30
AU2005209600A1 (en) 2005-09-29
KR20020088066A (ko) 2002-11-25
CZ20022411A3 (cs) 2003-02-12
EP1611892A3 (en) 2006-02-01

Similar Documents

Publication Publication Date Title
NO20022966L (no) Drospirenon for hormonerstatningsterapi
EP1598069A3 (en) Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
DE69627253T2 (de) Fenofibrathaltige neue galenische Arzneizusammensetzungen und ihre Verwendung
CA2366702A1 (en) Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
LU92060I9 (et)
MY121397A (en) Ziprasidone formulations
GB2364641A (en) Stabilized oral pharmaceutical composition containing iodide and iodate and method
BG104930A (en) 2-phenyl-1-[2-(-aminoethoxy)-benzyl]-indole in combination with estrogens
HK1047036A1 (zh) 用於治疗偏头痛的选择性iglur5，受体拮抗剂
IL139320A0 (en) Pharmaceutical compositions containing human parathyroid hormone
PL1559431T3 (pl) Kompozycja farmaceutyczna dla pochodnych peptydu trombiny
DE69706825D1 (de) Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen
GB9209882D0 (en) Compositions
YU46302A (sh) Supstituisani piroli
ATE224195T1 (de) Glucocorticoide zur behandlung von glomerulonephitis
AU2624499A (en) Oral compositions at low dosage of cytotoxic proteins
KR970061245A (ko) 프로제스테론 및 에스트로젠 작동약을 사용한, 뼈 손실 예방용 약학 조성물
Ivashin et al. Development of addiction to carbophos in the offspring of rats at administration during pregnancy.
WO2005041976A3 (en) Injectable gabapentin compositions

Legal Events

Date Code Title Description
HC1A Change of owner name
HC1A Change of owner name
HC1A Change of owner name